GLP-1 receptor agonist use in patients with minor stroke is associated with lower risk of post-stroke dementia
Authors:
- 7 November 2026
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (11) , 705
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (5U54GM104942-08)
This publication has 27 references indexed in Scilit:
- Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 DiabetesJAMA Internal Medicine, 2026
- Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive FunctionJAMA, 2025
- GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related DementiasJAMA Neurology, 2025
- Cardioprotective Glucose-Lowering Agents and Dementia RiskJAMA Neurology, 2025
- Cognitive Decline After First-Time Transient Ischemic AttackJAMA Neurology, 2025
- Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial studyeClinicalMedicine, 2024
- GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT+HG-induced toxicityHeliyon, 2023
- Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the USJAMA Neurology, 2022
- Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brainMolecular Metabolism, 2015
- Validation of Minor Stroke Definitions for Thrombolysis Decision MakingJournal of Stroke and Cerebrovascular Diseases, 2013